Kidney slices represent an in vitro model that has the cellular complexity of in vivo tissue to provide insights into mechanisms of organ injury, as shown in this study with the model nephrotoxicant cisplatin. Cell pathways altered by cisplatin exposure are assessed by gene expression analysis, cell function, and morphology in human and rat kidney slices in comparison to rat kidney from an in vivo study. The acute nephrosis of the tubular epithelium induced by cisplatin in vivo was reproduced in both human and rat kidney slices, while the glomerulus appeared resistant even at high concentrations. Kidney gene expression changes of in vivo and in vitro samples were indicative of transcription, DNA damage, cell cycle, proliferation, and apoptosis that are in agreement with the mechanism of cisplatin causing DNA damage, growth arrest, and apoptosis; while genes indicative of protein damage, the disruption of transport and calcium homeostasis, cellular metabolism, and oxidative stress are pathways linked with cisplatin binding to various cellular proteins and macromolecules. Both concentration and time-dependent gene expression changes evident in the in vitro model preceded a change in tissue morphology. Functional assays confirming cell dysfunction and increased apoptosis revealed the rat kidney to be more sensitive to the effects of cisplatin than human kidney as demonstrated by significant decreases in slice ATP and GSH levels, significant increases in caspase 9 and 3 activity, p53 protein levels, and increased DNA laddering. The regional markers of proximal and distal tubular injury, alpha-and pi-glutathione S-transferases, were shown for the human kidney slices to be significantly increased by cisplatin. In this study, cisplatin-induced nephrotoxicity was demonstrated morphologically in rat and human kidney slices, and the associated gene expression and functional changes characterized the cellular pathways involved.
INTRODUCTION
Cisplatin is an effective chemotherapeutic agent that displays dose-limiting nephrotoxicity. The renal toxicity induced by cisplatin is primarily tubular dysfunction, which progresses to acute renal failure. The kidney receives a high exposure to cisplatin, as the major route of cisplatin elimination via urine by filtration at the glomeruli and secretion in the proximal convoluted tubules. High doses of cisplatin will also cause hepatocellular injury, including elevations in AST, ALT, and rarely steatosis and cholestasis (Eder, 1997; Perez, 1998) .
Kidney slices represent an in vitro model which has the 3-dimensional cellular complexity and cellular interactions that are representative of in vivo tissues. The potential of this model for gaining mechanistic information is demonstrated with cisplatin as the model compound and with the integration of gene expression analysis, cell function and morphology in both animal and human tissue. Both our understanding of key cellular pathways leading to organ injury and our ability to focus on the clinical relevance of a potential outcome is enhanced through the application of human tissue to this in vitro model.
Cisplatin reacts with cellular molecules because it contains an electrophilic metal which forms a reactive hydrated species following the displacement of the chloride ligands by water. A variety of intra-and interstrand links and adducts with nucleic acids, proteins, and thiol containing molecules in cells and in the blood is associated with the pharmacological effect of cisplatin, as well as the inactivation of cisplatin and the disruption of cellular function (Nagai et al., 1996; Sadowitz et al., 2002) . The linking of DNA damage with the induction of cell cycle arrest and DNA damage-inducible genes correlates with enhanced apoptosis as a key pathway for cisplatin induced growth arrest. Cells with similar levels of DNA damage, however, can differ in the response to cisplatin. The threshold level or type of cellular injury induced by cisplatin depends on the extent of damage to proteins or molecules involved in the apoptotic pathway, resulting in either an unfinished apoptotic program or necrosis (Vasey et al., 1996; Delmastro et al., 1997; Gonzalez et al., 2001) . Cisplatin induced cellular injury is also in part a result of a decrease in the cellular antioxidant defense system through the direct binding of cisplatin to molecules such as glutathione or by an enhanced formation of reactive oxygen species. The binding of cisplatin to cellular proteins can result in the disruption of the function of various transport and storage proteins, including proteins that bind iron, thereby contributing to the increased formation of reactive oxygen species (Dehne et al., 2001; Gonzalez et al., 2001) .
In this study cisplatin induced acute nephrosis in rat and human kidney slices, which was preceded and accompanied by effects on gene expression and cell function. The integration of these technologies with kidney slices advances the potential use of this model for providing an in vivo insight to understanding the mechanisms of cellular injury as summarized in Figure 1 .
MATERIALS AND METHODS Chemicals
Cisplatin (dichloro-diamino-cis platinum II, CAS# 15663-27-1, purity 99.9%) and the chemicals used in the preparation of the preservation medium V7 were obtained from Sigma (St. Louis, MO). Cell culture medium, DMEM/F12, and antibiotic and antimycotic solution were obtained from Gibco BRL (Gaithersburg, MD), while Nu-Serum and MitoSerum Extender were obtained from Becton Dickinson (Franklin Lakes, NJ). Aerrane (isoflurane) was obtained from Amersham Life Sciences (Arlington Heights, IL). The bovine IgG standard was obtained from Bio-Rad (Hercules, CA).
Animals
Male Hanover Wistar rats (approximately 9-10 weeks old, 220-300 g), purchased from Harlan-Sprague Dawley (Dublin, Virginia), were used for the in vivo and in vitro studies. Animals were allowed free access to a Certified Rodent Diet #5002 from PMI Feeds (Richmond, IN) and water prior to the in vitro study and throughout the in vivo study. All animals were housed in a room kept at 72 • ± 2 • F and 55% ± 15% relative humidity, and were maintained on a light/dark cycle of 12 hours/12 hours. The animals were sacrificed mid-morning for both the in vivo and in vitro studies. All animals were handled and treated in accordance with the Novartis Animal Care and Use Committee of Novartis Pharmaceuticals Corporation (East Hanover, NJ).
In vivo Studies: Cisplatin was administered, in 0.9% sodium chloride and injected into the tail vein (5 mL/kg at 1 mL/min), either as a single dose (8 mg/kg) or as multiple doses (1 mg/kg) up to 4 doses (5 animals/group). Vehicle treated animals received 4 doses of saline. Blood samples were obtained for clinical pathology determinations at predose, and 48 hours, and at sacrifice (24 hours and day 5) via the retro-orbital venous plexus using light CO 2 (60%)/ O 2 (40%) anesthesia. Animals were euthanized with CO 2 /O 2 anesthesia and exsanguinations at 24 hours after the first dose and on day 5. Tissue samples (∼200 mg) of kidney (bilateral), collected for gene expression analysis, were snap frozen in liquid nitrogen and stored at −76 • C until analysis. The remaining kidney tissue was placed into 10% neutral-buffered formalin.
In vitro Studies: The rats were anesthetized with AErrane, euthanized by an incision in the diaphragm, and the kidneys were removed through a midventral incision and placed into cold V7 preservation solution.
Human kidneys, which were unsuitable for transplantation and accepted by Vitron, Inc. from various procurement agencies, were received with consent. These procurement Precision-cut rat and human kidney slices (∼200 ± 25 µm thickness) were prepared from cylindrical tissue cores (8 mm in diameter) in oxygenated, cold V7 preservation solution at ∼10 • C using a Vitron tissue slicer (Vitron Inc., Tucson, AZ). For the rat, whole kidney slices (cortex plus medulla) were used for morphology, gene expression and DNA laddering. The functional assays measurements reported here represent data from cortex slices, since initial measurements revealed that cortex only slices yielded the same results as whole slices. To prepares rat cortical slices, the medulla is cut away from the cortex using the coring tool, leaving a cortex slice in the shape of a crescent, and maximizes the tissue needed for the various assays. All slices were cultured using titanium roller inserts rotating at ∼2 rotations/minute and 37 • C (Fisher et al., 1994) . The rat kidney slices were maintained in DMEM/F12 medium (1.7 ml/vial) supplemented with 10% Nu-Serum, antibiotic/antimycotic (10 ml/liter) and Mito/Serum Extender (1.0 ml/liter) at 85%/5%:O 2 /CO 2 , and 90% humidity (Hereaus cytoperm). Human kidney slices were maintained in Waymouth's medium (1.7 ml/vial) supplemented with 10% fetal calf serum, Fungibact (10 ml/liter), and gentamicin (50 mg/liter) at 95%/5%:O 2 /CO 2 . Following a 1-hour preincubation, the medium was replaced with 1.7 ml of dosing medium for all cultures. Cisplatin was prepared in sterile water. Initially, pilot studies were performed to identify the concentrations at which significant changes of cell viability (ATP, GSH, K + ) were apparent by 24 hours of culture. The mechanistic studies were then performed under the following conditions: rat kidney slices 10-100 µM, human kidney slices 40-500 µM.
RNA Isolation: Whole kidney (bilateral) samples (∼200 mg) from the in vivo studies were disrupted in 4 ml of RNA lysis buffer (RLT buffer, Qiagen Inc) containing guanidinium isothiocyanate and 1% β-mercaptoethanol using a Powergen 125 homogenizer (Fisher Scientific) with a sterile 1 cm probe (30 seconds) then a 0.5 cm probe (30 seconds). The homogenate was centrifuged (10 minutes, 4,500 rpm) to pellet unbroken cells, an aliquot (10 µl) was collected for protein determination, and then total RNA was purified from the re-maining homogenate using the RNeasy Midi Kit (Qiagen Inc.). In brief, ethanol (70%, 4 ml) was added to the homogenate for dilution and to promote binding to the RNeasy column. Homogenate (∼4 ml) was applied to the RNeasy spin column, centrifuged at 4,500 rpm for 5 minutes, and the flow through discarded. This step was then repeated with the remaining 4 ml of homogenate. To remove contaminating genomic DNA, samples were subjected to an on-column DNase treatment with 160 µl DNase (2.7 Kunitz/µl) for 15 minutes at room temperature followed by a 1-minute spin at 4,500 rpm and reapplication of the DNase solution for an additional 15 minutes. The column was then washed extensively with RNeasy wash buffers, and the purified RNA eluted 2× with 150 µl of nuclease free water. RNA yield and purity was determined by measurement of the optical density of a 1/50 dilution of the samples at 260 and 280 nm using a SpectraMax Plus microplate spectrophotometer (Molecular Devices).
Rat kidney slices, consisting of cortex and medulla and derived from the bilateral regions of the kidney as for the in vivo samples, were placed in a 96-well tube rack containing 2 acid washed glass beads (3 mm diameter) and 500 µl of RNA lysis buffer as described previously. Slices were disrupted by vigorous shaking (3 × 1 minute at 30 Hz) in a QIAgen Mixer Mill. Slice homogenate was cleared of unbroken cells by spinning through a QIAfilter 96 plate (3000× g, 5 minutes) and an aliquot (10 µl) was collected for total protein content. Homogenates were treated with a proteinase digestion (10 µl of 600 units/ml proteinase K) for 20 minutes at 55 • C. Ethanol (70%, ∼500 µl) was then added to the remaining homogenate, the samples mixed by inversion, transferred to the RNeasy 96 plate, and centrifuged (6,000× g, 2 minutes). The column was washed with 700 µl of RW1 wash buffer (Qiagen Inc.) and the bound RNA was subjected to on-column DNase treatment (70 µl of DNase reaction buffer plus 10 µl of DNase at 2.7 units/µl) for 15 minutes at room temperature. Following extensive washing with RNeasy wash buffers, the purified RNA was eluted 2× with 50 µl of RNase free ddH 2 O.
The human kidney cortex slices were disrupted prior to snap freezing in 500 µl RNA lysis buffer and a Powergen hand held homogenizer as described before. Homogenates were then snap frozen in liquid N 2 and stored at −76 • C. After thawing, the homogenates were processed for RNA isolation as described before for the rat kidney slices.
The average yield of RNA was ∼10 µg/mg protein for in vivo and in vitro samples. RNA (2 µg) quality was assessed on a 1.25% agarose gel, stained with SYBR green (Molecular Probes), to visualize the integrity of the 18s and 28s rRNA, and hence the total RNA sample. Protein content was determined in the homogenate using a modified Bradford protocol. Tissue homogenate was diluted 1:40 with 0.1 N NaOH and an aliquot (10 µl, ∼10 ng protein) was added to a microtiter plate containing 200 µl of undiluted Bradford reagent (Sigma). After mixing, the absorbance at 595 nm was measured on a SpectraMax 340 plate reader and compared to a standard curve of bovine IgG (0-500 µg/ml).
cDNA Microarray Hybridization and Analysis: Total RNA (20 µg), prepared as a representative pool from individual animals or slices (up to 8 slices/concentration/time point) within a group, was processed for cDNA template preparation 580 VICKERS ET AL.
TOXICOLOGIC PATHOLOGY and array hybridization by Phase-1 Molecular Toxicology Inc. (Santa Fe, NM). Briefly, the total RNA was reverse transcribed to cDNA in the presence of Cy3 (Cy3-AP3-dCTP) for control samples and Cy5 (Cy5-AP3-dCTP) for treated samples. The fluorescence units in the purified probes were determined and normalized so equivalent amounts of each label were added to each microarray slide. The resultant purified cDNA from a treated sample and its respective control was hybridized overnight at 42 • C to a single microarray (∼250 genes/rat array, ∼350 genes/human array). The arrays were subsequently extensively washed and the fluorescence intensities of the Cy3 and Cy5 channels read using a GenePix 4000B scanner and the Gene Pix Pro 3.0 software (Axon Instrument Inc., Foster City, CA). The Phase-1 Toxicology arrays contain single stranded oligonucleotide probes (∼250-500 base pairs covalently linked to the array) for genes known to be transcriptionally regulated under conditions of cellular adverse events. Data produced from the arrays was deposited into a MATRIXexpress 2.0 program developed by Phase-1. Gene expression data was analyzed using summary scores of the treated to control ratio on a gene-by-gene basis (4 replicates probes/gene/chip, ≥1.75-fold change, 30% cov), which were averaged and normalized to the total fluorescence across the slide using the Phase-1 MATRIXexpress program. Genes were discounted if the coefficient of variation between replicates was >50%. As the chip evolved expression profiles of gene changes ≥1.75-fold were compared from replicate analyses, for reproducibility, and for similarity within gene categories as new gene probes were added to the chips, as well as for similarity across the compound treatments, and for dose-dependent effects. Gene changes considered to be relevant were those genes induced/repressed in at least 2 of 3 independent experiments, and gene changes occurring for at least 2 concentrations, suggesting a dose-dependent effect.
Branched DNA (bDNA): Oligonucleotide probe sets designed for rat mRNA gene sequences included gadd45 (accession no. L32591, nucleotides 42-435), p53 (accession number X13058, nucleotides 246-905), clusterin (accession no. BC061534, nucleotides 238-1115), metallothionein (accession no. BC058442, nucleotides 87-239) and 28S rRNA (accession number V01270, nucleotides 5147-5806) from the GenBank public database www.ncbi.nlm.nih.gov/entrez/ nucleotide.html . All coding sequences were scanned for regions of significant homology (>80%) with all other known genes in the rat genome using NCBI's Blast 2.0 sequence similarity search tool www.ncbi.nih.gov/blast . Unique regions of ∼600-900 bp of contiguous coding sequence from each gene were used to design anti-sense probe sets consisting of ∼32 oligonucleotide probes (20-30 bp long) with an average melting temperature of 63 • C. The Probe Designer software (version 1.0, Bayer Diagnostics) was used to facilitate probe set design. Approximately 150 nM of purified oligonucleotide was synthesized by Perkin Elmer Applied BioSystems (Foster City, CA City). The Quantigene Signal amplification, branched DNA (bDNA) gene expression system (Genospectra) was used to quantitate kidney slice mRNA levels. Total kidney slice RNA (2 µg) was hybridized with an aliquot (100 µl containing 50 fM CEs, 200 fM LEs, and 100 fM BLs) of a gene specific probe set, overnight at 53 • C in a 96-well oligonucleotide coated bDNA plate. Hybridization was followed by a series of wash steps to remove unbound probes and RNA. A luminescent substrate (dioxetane; 50 µl) was added and the plate incubated at 37 • C for 30 minutes prior to quantitation of the luminescent signal using a Quantiplex luminometer (Bayer diagnostics and Dynex technologies). The average relative light units (RLUs) produced are normalized to values obtained for the housekeeping gene, 28S ribosomal RNA.
Slice Viability: The slices analyzed for ATP and GSH were weighed, homogenized in 10% trichloroacetic acid with a Powergen 125 at room temperature, snap frozen in liquid nitrogen, and stored at −76 • C. Upon analysis the slice homogenates were thawed and centrifuged (11,000× g, 10 minutes, 4 • C). For the ATP determination, an aliquot (4 µl) of slice homogenate was added to a white 96-well flat bottomed Microlite 1+ plate (Dynex Technologies; Chantilly, VA) containing 6.0 µl of 0.5 M Tris-1 mM EDTA buffer (pH 8.9). The plate was loaded into a Victor 2, 1420 Multilabel counter that injected 100 µl of luciferin plus luciferase reagent (ATP determination kit, Molecular Probes), shaken for 1 second and the luminescence read. The values were extrapolated from a standard curve of ATP (0-100 µM). Data is presented as nmoles ATP/mg slice wet weight.
For GSH measurements, an aliquot of slice homogenate (50 µl) was transferred to a 96-well microtiter plate, and 200 µl of Ellman's reagent (39.6 mg dithiobis-nitrobenzoic acid/10 ml EtOH diluted 1:10 with 0.5 M Tris-1 mM EDTA buffer pH 8.9) was added. The absorbance was determined at 405 nm using a SpectraMax 340 plate reader from Molecular Devices (Sunnyvale, CA) and the values extrapolated from a standard curve of reduced glutathione (0-250 µM). Data is presented as nmoles GSH/mg slice wet weight.
Caspase 9 and 3 activities were measured in slice homogenates using the caspase specific peptide conjugated to a fluorescent reporter LEHD-AFC (caspase 9) and DEVD-AFC (caspase 3) provided by R&D Systems. The kidney slices were homogenized in 500 µl of cold cell lysis buffer and centrifuged at 3,000× g for 5 min at 4 • C. An aliquot (50 µl) of the homogenate was added to a microtiter plate and combined with 50 µl reaction buffer (prepared with 10 µl of fresh DDT per ml of 2× reaction buffer) and 5 µl of fluorogenic peptide, DEVD-AFC for caspase 3 and LEHD-AFC for caspase 9. Plates were incubated at 37 • C for 1-2 hours and the fluoresence read (excitation 405 nm, emission 510 nm) every 10 minutes for 70 minutes using a Wallac Victor 420 Multilabel Counter. The results are expressed as fluorescence/min/µg protein.
Immunoassays: The leakage of α-GST and pi-GST into the culture medium from the human kidney slices was measured according to the Hepkit-Alpha and Hepkit-Pi enzyme immunoassays (Biotrin International, Dublin, Ireland). Aliquots (100 µl) of human kidney slice homogenate (∼2 µg protein/ml for α-GST, ∼150 µg/ml for pi-GST) and medium free of cell debris (diluted 300-500× for αGST, no dilution for pi-GST) were added to microtiter plates precoated with a monospecific antibody for either human αGST or π -GST. The optical density following color development was read at 450 nm for both assays with unknown values extrapolated from the standard curve. Data is presented as the percent GST Vol. 32, No. 5, 2004 CISPLATIN INJURY IN RAT AND HUMAN KIDNEY SLICES 581 released (% GST in the medium/ total GST in the slice and medium). p53 slice protein levels were determined in aliquots of kidney slice homogenates (100 µl, ∼1.5 mg protein) added to a streptavidin-coated microtiter plate with an anti-human-p53 polyclonal antibody, that cross-reacts with rat, and processed according to the p53 pan ELISA Kit (Roche Molecular Biochemicals, Mannheim, Germany). Absorbance at 450 nm was determined on a SpectraMax 340 plate reader using 690 nm as a reference. The p53 values were extrapolated from a standard curve (0-1,150 pg/ml) and expressed as pg p53 protein/µg total slice protein. The p53 protein content was also measured in the medium, however, levels of p53 protein were below the minimum detectable levels for the assay.
DNA Laddering: Genomic DNA was purified from tissue and slices using the QIAamp Tissue Kit (Qiagen Inc.) following disruption with a Pellet Pestle homogenizer (Kontes), in phosphate buffered saline (pH 7.0) at room temperature. Prior to DNA purification, kidney slice homogenates were subjected to Proteinase K and RNase A treatment to remove contaminating protein and RNA from the sample. Lysis buffer (120 µl) containing Proteinase K (20 mg/ml) was added to the slice homogenate and digestion was carried out at 55 • C with constant mixing (55 rpm; Precision Scientific, shaking water bath) for 90 minutes followed by a 2-minute RNase A (20 mg/ml) digestion at room temperature. A 1/2-volume of 100% EtOH was added, and the sample was applied to a QIAamp, silica gel spin column. The samples were centrifuged at 6,000× g for 1 minute and the flow through was discarded. The DNA bound to the column was extensively washed. Elution buffer (200 µl, preheated to 70 • C) was added followed by a 5-minute incubation at room temperature and centrifugation for 5 minutes at 10,000× g. This process was repeated 2 times to ensure complete elution of the DNA from the column. The DNA was concentrated by isopropanol precipitation for at least 1 hour at −76 • C. Samples were centrifuged for 10 minutes at 10,000× g, the supernatant was removed and the DNA containing pellet was rinsed with 70% EtOH. The resulting DNA was dried using a Jouan RC 10.10 vacuum dryer and resuspended in 25 µl of ddH2O. Yield and purity of DNA was determined by measurement of the optical density, of a 1/100 dilution of the samples, at 260 and 280 nM using a Perkin Elmer Lambda 2S spectrophotometer or a SpectraMax plus microplate spectrophotometer. An OD260 of 1 corresponds to a 50 µg/ml DNA solution. Average yield of DNA per slice was ∼15 µg (∼0.8 µg/mg tissue, wet weight). Slice genomic DNA (5 µg), and molecu- lar weight size standards, were separated electrophoretically on a 1.5% agarose gel (TreviGel 500, Genzyme Diagnostics) to visualize and quantitate DNA laddering. The gel was run at 70 volts for approximately 3-4 hours and the DNA was stained with Vistra Green DNA stain (Molecular Dynamics) for at least 2 hours (overnight if necessary). Apoptotic banding of the DNA was detected and volumetric quantitation of the smallest 2 DNA fragments (∼180 and 360 bp) was calculated using a STORM molecular imager (Molecular Dynamics) with ImageQuant for windows NT (V-4.2A) software.
Histopathological Analysis: Kidney slices were floated off the insert by gently shaking the insert in warmed (37 • C) medium. The slice was then laid flat in a 6-well culture dish. Any remaining medium was removed and 2-3 drops of 10% neutral buffered formalin were dropped on top of the slice. After 10 minutes, additional formalin was added on top of the slice. After 1 hour of fixing in formalin, the slice was rinsed in 80% ethanol and then stored in 80% ethanol at 4 • C paraffin until embedding. Slides, 5-µm sections, were cut and stained with hematoxylin and eosin using a standard procedure for light microscopic evaluation.
Statistical Evaluation: The clinical chemistry analysis was performed on the value differences from baseline of treated and control groups using SAS 6.12 for the Windows NT platform. For the in vitro studies an ANOVA followed by 2-sided Dunnett's multiple comparison tests was employed with Graphpad Prism Software version 2.01 (Graphpad Software, Inc,; San Diego, CA). Treatment groups were compared to the respective control group. Values were considered significantly different if p < 0.05.
RESULTS

Rat in vivo Clinical and Histopathology
Cisplatin, administered as a single dose of 8 mg/kg, caused kidney dysfunction in rats. By day 3 statistically significant increases of BUN, creatinine and AST were evident compared to predose values, which further increased by day 5 for BUN (∼5.5-fold) and creatinine (∼6.5-fold). Proteinuria and glucosuria occurred on days 3 and 5 (Table 2) . Multiple low doses of cisplatin (1 mg/kg/day) had no effect on the clinical chemistry parameters.
Widespread degenerative and regenerative changes of the tubular epithelium resulted from the single dose of cisplatin (8 mg/kg). Many tubules contained either granular or proteinaceous casts and some randomly scattered tubules were mineralized ( Figure 2 ). Regenerative changes were characterized by the presence of basophilic tubules whose nuclei were plump. Animals receiving multiple doses of cisplatin (1 mg/kg/day) had similar but less extensive kidney changes to those of the 8 mg/kg animals.
Rat Gene Expression
Kidney gene expression of the 1 mg/kg (4-doses) and 8 mg/kg (1-dose) in vivo samples at 96 hours reveal changes indicative of cell cycle regulation, general and oxidative stress, and transport (Table 3 ). The increased expression of gadd45 suggested that growth arrest was important. This became further elaborated by in vitro studies which revealed both DNA damage and transcription genes to be affected by cisplatin treatment. Confirmation of the microarray gene expression changes was verified by the bDNA method for selected genes including, gadd45, p53, metallothionein 1 and clusterin ( Table 3 ). The RNA pool for each group was considered reflective of the gene changes induced by cisplatin, since each animal within the cisplatin groups displayed morphological Rat kidney whole (cortex plus medulla) slices exposed to cisplatin (20-40 µM) exhibited gene expression changes of cellular functions and pathways similar to the in vivo findings (Table 3) . Gene expression changes indicative of transcription, DNA damage, cell cycle, proliferation, and apoptosis are in agreement with the mechanism of cisplatin causing DNA damage, growth arrest, and apoptosis. The expression of genes associated with general and oxidative cellular stress, and calcium homeostasis are pathways linked with cisplatin binding to various cellular proteins and macromolecules. The potential disruption of cellular transport processes is evident from the gene expression changes. Only the kidney slices displayed gene expression changes indicative of altered mitochondrial function. The RNA isolated from the 60-100 µM cisplatin exposed slices was not suitable to undergo the reverse transcription reaction and microarray Vol. 32, No. 5, 2004 CISPLATIN INJURY IN RAT AND HUMAN KIDNEY SLICES 583 analysis, suggesting that cisplatin exposure had effected the RNA integrity. In comparing the gene expression changes between the in vivo and in vitro samples, it is evident that the expression of many of the genes and categories represented by the genes are the same. Differences in the cisplatin exposure, duration of exposure, and extent of injury between the 2 systems may explain the direction of the gene expression change at the indicated time-point. The in vivo samples (96-hour) represent a further progression of the acute tubular nephrosis in terms of the gene expression profile and the morphology than the in vitro (24-hour) samples used for gene expression analysis (20 and 40 µM). Greater morphological change was evident with 60 and 80 µM cisplatin. Furthermore, the expected effects on transcription and DNA damage gene expression were more evident in the in vitro samples, suggestive of the time-course and concentration dependent effects on gene expression.
Morphology of Kidney Slices
Whole rat kidney (cortex plus medulla) slices exposed to cisplatin (10-80 µM) exhibited morphological changes consistent with acute nephrosis within the cortex and at the junction between the cortex and the outer stripe of outer medulla. The nephrosis was concentration dependent and characterized by swelling and vacuolation of the tubular epithelium, tubular dilation, epithelial sloughing into the tubular lumina, loss of normal histologic architecture, and multifocal areas of tubular epithelial cell degeneration and necrosis (Figure 3) . The glomerulus was not affected until very high concentrations of cisplatin. Human kidney cortical slices, and cortical-medulla slices, exposed to cisplatin (40-500 µM) displayed an altered morphology in the renal tubular epithelium while the glomerular components appeared resistant. The morphological changes were consistent with acute nephrosis and were located mostly in the convoluted tubules in the cortex. The severity of the nephrosis was concentration-and time-dependent with the earliest lesions observed in the 160 µM 12-hour treated slices (Figure 4) . The extent of swelling and necrosis progressed to involve all parts of the convoluted tubules at the higher concentrations and 24-hour time point.
Human Kidney Gene Expression
Human kidney slices were exposed to cisplatin, 40-500 µM 12-hour and 40-100 µM 24-hour, for the gene expression analysis. The quality of the human tissue was found to be critical for obtaining high quality RNA, based on RNA yield, purity, and RNA integrity, to perform successful genechip analyses. Each human tissue used in this study had intracellular K + levels >70 µmoles/gm slice wet weight at the start of the experiment, and maintained high K + values after 24 hours of culture.
The gene expression changes indicated that cisplatin affected similar cellular functions and pathways in the human kidney cortical slices as in the rat kidney cortical slices. Concentration-dependent gene expression changes after a 12-hour exposure to cisplatin (40-500 µM) demonstrated an effect on DNA transcription, DNA damage, growth arrest, and cell cycle (Table 4) . Additionally, gene expression associated with protein damage, intracellular signaling, transport, and calcium homeostasis were effected at 12 hours. Exposure to cisplatin (20-100 µM) for 24 hours altered the expression of the same and of additional genes within the cellular functional categories/pathways as noted for 12 hours. The key gene expression changes at 24 hours and for the concentrations revealing the cisplatin dose-dependent changes are shown for 40 and 80 µM (Table 4 ). Gene expression changes indicative of an inflammatory response were more evident at 24 hours. Human kidney slices derived from the cortexmedulla junction of an experiment in which the cortical slices were evaluated, exhibited gene expression changes as shown for the cortex-derived slices or genes indicative of the same category at 80 µM cisplatin (data not shown).
Functional Assays
Rat kidney slices were more sensitive to cisplatin, exhibiting greater changes in slice viability at lower cisplatin concentrations, as compared to human kidney slices. Both ATP and GSH rat kidney slice levels displayed a concentrationdependent and significant decrease, reaching a 50% depletion at ∼60 µM cisplatin ( Figures 5 and 6 ). Human kidney slices began to exhibit significant decreases in GSH levels at 160 µM cisplatin at 24 hours, and at 40 µM by 48 hours. Slice ATP levels were minimally affected and generally comparable to the control slice values.
Cisplatin induced significant increases of caspase 3 activity in human kidney slices, 40-240 µM by 24 hours, which persisted through 48 hours (Figure 7) . The significant increase of caspase 9 activity in human kidney slices (40-240 µM at 48 hours), and in rat kidney slices (10-80 µM, 12 hours), suggests the involvement of mitochondria in the apoptotic pathway, which can be activated independently or by crosstalk with other caspases.
Regional markers of tubular injury include α-glutathione S-transferase, a marker of proximal tubules, and piglutathione S-transferase, a marker of distal tubule injury. Cisplatin exposure to human kidney slices caused a significant increase in the release of α-GST and pi-GST rather than an increased synthesis in the slices, suggesting injury to both regions of the tubules (Figure 8) .
The involvement of a p53-dependent pathway by cisplatin was characterized by an increase in slice p53 protein levels. Cisplatin induced p53 protein levels significantly in human kidney slices throughout the duration of the cultures (Figure 9 ). In rat kidney slices, p53 protein levels were significantly increased in either cortex-only slices (Figure 9 ) or cortex-medulla slices (data not shown).
An increase in the specific cleavage and fragmentation of DNA, reflected as an increased DNA laddering of the 180-220 bp fragments, was apparent in human kidney and rat kidney slices exposed to cisplatin ( Figure 10 ). In the rat in vivo study, 1 mg/kg single dose cisplatin, both kidney and liver samples from 1 of 5 animals revealed an increased DNA laddering on the gel (data not shown). TOXICOLOGIC PATHOLOGY of the in vitro model for extrapolating animal findings and identifying cisplatin-induced effects for humans. Cisplatin exposure caused nephrosis in both the rat and human kidney slices. A progressive involvement of the tubular system was evident for both species in the in vitro model. In both species the glomerular structures were particularly resistant. Other studies in the rat have demonstrated that cisplatin induces acute tubular necrosis of the straight portion of the proximal tubule, located at the cortico-medullary junction (Choie et al., 1981; Chopra et al., 1982) .
DISCUSSION
Cisplatin induced kidney injury was investigated in human kidney slices by correlating the changes in gene expression
In humans, only a few studies describe the pathology associated with cisplatin-induced nephrotoxicity. The sites of injury include the distal tubules and collecting ducts or the proximal and distal tubules (Hardaker et al., 1974; Piel and Perlia, 1975; Dentino et al., 1978; Gonzalez-Vitale et al., 1978) . These site differences may be due to the differences in dose and time at sampling. Biopsies collected from 3-60 days reveal a segmental degeneration, necrosis, and desquamation of the epithelial cells in the pars convoluta and pars recta of the proximal tubule and distal tubules followed by the collecting ducts (Tanaka et al., 1986) . A difference in cisplatin toxicity between rats and humans has been suggested to be a consequence of the difference in the cellular distribution of metallothionein, a cellular protein that can bind significant amounts of metal ions including cisplatin to protect the kidney from injury and serve as a regulator for apoptosis (Hosokawa et al., 2000; Satoh et al., 2000; Hagrman et al., 2003; Shimoda et al., 2003) . Cisplatin has been shown to induce metallothionein mRNA and protein in the kidney cortex of male Wistar rats, while DNA damage occurred at the outer stripe of the outer medulla, the cortical-medullary junction. In mice that lacked metallothionein cisplatin increased liver apoptosis and DNA fragmentation (Liu et al., 1998) .
In this study the gene expression changes induced by cisplatin reflected multiple cellular functions and pathways in rat and human kidney slices. Concentration and time dependent gene expression changes preceded the morphological change as shown in human kidney slices. The panel of gene expression changes, DNA damage, cell cycle, general and oxidative stress, transport, metabolism, inflammation, and calcium homeostasis is consistent with our current knowledge of cellular pathways and functions comprising cisplatin nephrotoxicity (Gonzalez et al., 2001; Huang et al., 2001; Niedner et al., 2001) . Furthermore, many of the gene expression changes noted in this Wistar rat in vivo study (8 mg/kg) were evident in a recently reported Sprague-Dawley rat in vivo study (5 mg/kg) (Thompson et al., 2004) .
Cisplatin nephrotoxicity is initially characterized by dysfunction of the proximal tubular cells, affecting the transport of water, nutrients, and electrolytes. In this study, gene expression of several transport proteins was altered by cisplatin in the rat and human kidney slices. Other studies have demonstrated that transport at the renal brush border following cisplatin treatment is decreased, in particular the Na +dependent transport of glucose and phosphate (Halabe et al., 1991) . Transporters, which directly bind cisplatin, may affect tubule transport dysfunction. For example, the organic cation transporters preferentially mediate the secretion of cisplatin into urine, the major route of cisplatin elimination (Fisher et al., 1994; Endo et al., 2002) , while the ATP-dependent GS-X pump mediates the export of cisplatin-glutathione con-jugates (Ishikawa et al., 1994) . Inhibition of glutathione Stransferase or the glutathione export pump, however, have been shown to have no effect on cisplatin toxicity, in spite of the glutathione depletion by cisplatin (Chen and Zeller, 1991; Perez, 1998; Zhang et al., 2001) . Suppression of the p-glycoprotein efflux pump at the gene and protein level by cisplatin suggests a role of transporter molecules in regulating cell survival and may be linked to the apoptotic signal induced by cisplatin (Ihnat et al., 1997; Johnstone et al., 2000) .
The cellular response toward cisplatin induced damage could lead to cell death either by apoptosis or necrosis Lieberthal et al, 1996; Lieberthal et al, 1998; Erdinc et al., 2000; Rixe 2000; Gonzalez et al., 2001) . A critical regulator of cisplatin induced growth arrest and apoptosis is activation of p53, which in turn activates the transcription of genes that promote apoptosis, cell cycle regulation, and represses the transcription of genes that inhibit apoptosis. p53 also plays a role in nucleotide excision repair following UV radiation and cisplatin via the regulation of growth arrest genes that induce G2 arrest and contribute to the repair of DNA (Jones et al., 1998; Fan and Bertino, 1999; Wang et al., 1999; Sheikh et al., 2000; Smith et al., 2000) . Apoptosis induced by cisplatin most likely occurs via several signalling pathways considering the reactivity of cisplatin to nucleic acids, proteins, and cellular molecules. The modulation of apoptosis via a kinasedependent pathway to induce MEKK1 cleavage, yielding a loss of mitochondrial integrity and caspase activation has also been demonstrated with cisplatin (Mandic et al., 2001) . In this study apoptosis and mitochondrial involvement was evident by the up-regulation of p53 gene expression that coincided and preceded an increase of p53 protein expression, by the increased activity of caspase 9 and 3, by the perturbation in the expression of genes indicative of calcium homeostasis, and by a characteristic DNA laddering pattern. Potential biomarkers of kidney injury that can be measured in urine and that were altered by cisplatin in the human kidney slice cultures include the αand π -glutathione S-transferases. Immunohistochemical localization studies have demonstrated the proximal tubules to be rich in α-GSTs and the distal convoluted tubules and collecting ducts to contain π-GSTs (Campbell et al., 1991; Sundberg et al., 1993 Sundberg et al., , 1994 .
Cisplatin has been shown to damage molecules involved in the cellular energy supply, ATP, and anti-oxidant supply, GSH, in several in vitro and in vivo models (Perez, 1998) . The extent of cellular damage could affect the pathway toward apoptosis or necrosis (Gonzalez et al., 2001) . Studies suggest that depletion of ATP levels to less than 50% is sufficient for the inhibition of apoptosis and leads to necrosis (O'Brien et al., 2000) . Moreover, changes in cellular metabolism, as suggested by the gene expression changes in this study, may contribute to a reduced glycolytic flux and supply of adequate substrates to mitochondria to maintain the membrane potential and cell viability (Plas and Thompson, 2002) . The oxidative stress induced with cisplatin in this study was manifested by a depletion of GSH and associated with gene changes indicative of protein damage and iron utilization. It has been hypothesized that the cisplatin-induced cell damage may in part be the result of an iron-dependent pathway and the formation of superoxide anions as suggested by the induction of heme oxygenase, as well as kidney heme and ferritin content Vol. 32, No. 5, 2004 CISPLATIN INJURY IN RAT AND HUMAN KIDNEY SLICES 589 (Agarwal et al., 1995; Shiraishi et al., 2000; Dehne et al., 2001) .
The results of this study support our current understanding of cisplatin-induced nephrotoxicity. This mechanism is complex involving several pathways involved in injury, inflammation, repair, recovery, and cell death. The comparison of effects in rat and human kidney slices demonstrated that similar cellular pathways were altered in both species yet exhibited differences in the sensitivity toward the injury. This study also demonstrates that the integration of gene expression profiling with functional assays and morphology strengthens the in vitro models for predicting cellular pathways of organ injury.
